We have followed the guidance set by the GMC, MHRA, NHS England.
We have gone beyond this guidance to create our own rigorous Standard Operating Procedures, which are being ratified by the above organisations and will be published on our site in due course. This will guide the future use of medicinal cannabis by closely monitoring adverse events and change in patient outcomes.
We have recruited experienced NHS consultants who are experts in their fields and will only see patients who they would see in their practice in the NHS.
We are aligned to the most up to date research and will continually monitor any new developments.
We will collect data on all of our patients with their consent and will form the first UK registry on medicinal cannabis. This will guide the future use of cannabis, adverse reactions and change in patient outcome to establish where this drug is of most use.